Lilly will provide an initial payment to complete a Phase I trial of OLX75016, which started in February 2024.

Byline: Hank Popeil In the ever-evolving landscape of healthcare, groundbreaking innovations are not merely celebrated for their scientific ingenuity but for their potential to radically improve human ...

These drugs belong to a class known as glucagon-like peptide receptor agonists (GLP-1RAs), which mimic a natural hormone that ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Viking Therapeutics stock jumped higher last year because it looks like a dual GLP-1/GIP agonist it's developing could ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

While first-generation glucagon-like peptide-1 receptor agonists have clearly taken the obesity market by storm, generating billions of dollars for Novo Nordisk A/S and Eli Lilly and Co., several ...

FDA approves third insulin biosimilar Merilog to ease U.S. supply shortage FDAs latest insulin biosimilar approval aims to mitigate ongoing supply challenges in the U.S.

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

When celebrities reveal their experiences with newer weight-loss drugs, there are upsides and downsides for patients and ...

Semaglutide — the active ingredient in the brand-name meds Ozempic, Wegovy, and Rybelsus — treats type 2 diabetes and obesity ...